STRO vs XRAY · rev $62.0M vs rev $3.68B
Sutro Biopharma (STRO) versus Dentsply Sirona Inc (XRAY) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Dentsply Sirona Inc (XRAY) is a medical instruments & supplies company listed on NASDAQ.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
Latest reported XRAY revenue for 2025-12-31 was $3.68B. Net income was -$598.0M. Revenue was down 3.0% from 2024-12-31 to 2025-12-31. XRAY currently screens at market cap $2.01B.
STRO currently screens at market cap $470.8M. XRAY currently screens at market cap $2.01B.
Not investment advice. Open the STRO and XRAY stock pages for the full models.
Not investment advice.